Bibliografía del artículo
1. Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986; 315:1575-8.
2. Manns MP, McHutchinson JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-65.
3. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2ª plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
4. Poynard T, McHutchinson JG, Manns M, et al. Impact of pegylated alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122(5):1303-13.
5. Berg T, Von Wagner N, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: Comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130:1086-1097.
6. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsman Y, Cianciara J et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44:97-103.
7. Mangia A, Santoro R, Minerva N, Ricci GL, Caretta V, Perisco M et al. Peginterferon alfa-2b and ribavirin for 12 vs 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352:2609-2617.
8. Von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, et al. Peginterferon alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129:522-527.
9. Davis GL. Tailoring antiviral therapy in hepatitis C. Hepatology 2006; 43:909-911.
10. Nishiguchi S, Shiomi S, Nakatani S et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrosis. Lancet 2001; 357:196-197.
11. Takimoto M, Ohkoshi S, Ichida T et al. Interferon inhibits progression of liver fibrosis and reduces the risk of hepatocarcinogenesis in patients with chronic hepatitis C: a retrospective multicenter analysis of 652 patients. Dig Dis Sci 2002; 47:170-6.
12. Ikeda K, Saitoh S, Kobayashi M et al. Long-term interferon therapy for 1 year or longer reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: a pilot study. J Gastroenterol Hepatol 2001; 16:406-15.
13. Papatheodoridis GV, Papadimitropoulos VC, Hadziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. Aliment Pharmacol Ther 2001; 15:689-98.
14. Camma C, Giunta M, Andreone P, Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001; 34:593-602.
15. Soga K, Shibasaki K, Aoyagi Y. Effect of interferon on incidence of hepatocelullar carcinoma in patients with chronic hepatitis C. Hepatogastroenterology 2005; 52:1154-8.
16. Hino K, Kitase A, Satoh Y, et al. Interferon retreatment reduces or delays the incidence of hepatocellular carcinoma in patients with chronic hepatitis C. J Viral Hepat 2002; 9:370-376.
17. Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003; 37:443-451.
18. Patel K, Muir AJ, McHutchison JG. Diagnosis and treatment of chronic hepatitis C. BMJ 2006; 332:1013-1017.
19. Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126:1015-1023.
20. Taliani G, Gemignani G, Ferrari C, Aceti A, Bartolozzi D, Blanc PL, et al. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. Gastroenterology 2006; 130:1098-1106.
21. Younossi ZM, McCullough AC, Barnes DS, Post A, Ong JP, O'Shea R, et al. Pegylated interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C. Dig Dis Sci. 2005; 50:970-5.
22. Shiffman ML, Diago M, Tran A, Pockros P, Reindollar R, Prati D, et al. Chronic hepatitis C in patients with persistently normal alanine transaminase levels. Clin Gastroenterol Hepatol 2006; 4:645-652.
23. Zeuzem S, Diago M, Gane E, Reddy KR, Pockros P, Prati D, et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004; 127:1724-1732.
24. Alberti A, Clumeck N, Collins S, et al. Short statement of the first European consensus conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005; 42:615-624.
25. Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al. Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV-Infected patients. N Engl J Med 2004; 351:438-450.
26. Lichterfeld M, Haas S, Fischer HP, Voigt E, Rockstroh JK and Spengler U. Liver histopathology in HIV-hepatitis C virus co-infected patients with fatal liver disease. J Gastroenterol Hepatol 2005; 20:739-745.
27. Moreno A, Bárcena R, García-Garzón S, et al. HCV clearance and treatment outcome in genotipe 1 HCV-monoinfected, HIV-coinfected and liver transplanted patients on peg-IFN-2b/Ribavirin. J Hepatol 2005; 43:783-790.
28. Bräu N. Chronic hepatitis C in patients with HIV/AIDS: a new challenge in antiviral therapy. J Antimicrob Chemother 2005; 56:991-995.
29. Yedibela S, Schuppan D, Muller V, Schellerer V, Tannapfel A, Hohenberger W, et al. Successful treatment of hepatitis C reinfection with interferon- alpha 2b and ribavirin after liver transplantation. Liver Int 2005; 25:717-22.
30. Berenguer M, Prieto M, Palau A, Carrasco D, Rayon JM, Calvo F, et al. Recurrent hepatitis C genotype 1b following liver transplantation: treatment with combination interferon-ribavirin therapy. Eur J Gastroenterol Hepatol 2004; 16:1131-3.
31. Inove K, Yoshiba M. Interferon combined with cyclosporine treatment as an effective countermeasure against hepatitis C virus recurrence in liver transplant patients with end-stage hepatitis C virus related disease. Transplant Proc 2005; 37:1233-4.
32. Bizollon T, Adham M, Pradat P, Chevallier M, Ducerf C, Baulieux J, et al. Triple antiviral therapy with amantadine for IFN-ribavirin nonresponders with recurrent posttransplantation hepatitis C. Transplantation 2005; 79:325-9.
33. Oton E, Bárcena R, García-Garzón S, Moreno Zamora A, Moreno A, García González M, et al. Pegylated interferon and ribavirin for the recurrence of chronic hepatitis C genotype 1 in transplant patients. Transplant Proc 2005; 37:3963-4.
34. Dumortier J, Scoazec JY, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004; 40:669-74.
35. González Peralta RP, Kelly DA, Haber B, Molleston J, Murray KF, Jonas MM et al. Interferon alfa 2b in combination with ribavirin for the treatment of chronic hepatits C in children: efficacy, safety and pharmacokinetics. Hepatology 2005; 42:1010-8. 36. Wirth S, Pipier-Boustani H, Lang T, Ballauff A, Kullmer U, Gerner P et al. Peginterferon alfa-2b plus ribavirin treatment in children and adolescent with chronic hepatits C. Hepatology 2005; 41:1013-8.